

Esperion Therapeutics

Pharma & biotech
14 August 2013

Investment summary: Statin alternative

Esperion's recent NASDAQ IPO raised \$75m net (5.75m shares at \$14/s), providing the funds to advance its once-daily ETC-1002 through two Phase IIb studies in hypercholesterolemia. ETC-1002 has shown LDL-C reductions comparable to statins thus far in statin-intolerant (SI) patients, which if repeated in future trials represents a potential blockbuster market opportunity, although long-term safety must also be established.

ETC-1002 investigated as new cholesterol treatment

ETC-1002 is an oral small molecule, which inhibits ATP citrate lyase (ACL) and activates AMP kinase, thereby enabling the liver to take up low-density lipoprotein cholesterol (LDL-C) particles from the blood. Esperion's initial strategy is to develop ETC-1002 for patients with high LDL-C who are SI, for example due to muscle pain or weakness, reflecting approximately two million adults in the US alone.

Competitive LDL-C reductions in Phase IIa studies

ETC-1002 lowered LDL-C by a mean 32% in an eight-week Phase IIa (n=56) trial in SI patients and was well tolerated, with a similar incidence of muscle-related adverse events as placebo. High-sensitivity C-reactive protein (hsCRP), a key inflammation marker, was also reduced to levels comparable to statin therapy. Esperion will start a 12-week Phase IIb trial (n=322) in this group in October (results Q414) comparing ETC-1002 to ezetimibe. The most-prescribed LDL-C lowering drugs in SI patients (ezetimibe or colesvelam) reported 15-18% mean LDL-C reductions in pivotal trials (vs 35-60% for statins), with little effect on hsCRP.

Statin-resistant patients are a broader target market

Esperion is also advancing ETC-1002 as an add-on to statins in statin-resistant hypercholesterolemia patients (c 11m adults in US alone). Results from a Phase IIa (n=52) study of ETC-1002 with atorvastatin are expected in early September, a significant near-term catalyst.

Valuation: \$177m EV discounts development risk

We estimate Esperion's post-IPO net cash at \$91m. The two Phase IIb trials will increase the burn rate (from \$10.8m in FY12), but Esperion estimates it has sufficient funds to complete these studies and start a Phase III trial in SI patients in 2015. The current EV of \$177m discounts the multi-billion dollar sales opportunity, hence confirmation of LDL-C reductions in Phase IIb and solid long-term animal safety data should provide upside.

Consensus estimates

Year end	Revenue (\$m)	PBT (\$m)	EPS (\$)	DPS (\$)	P/E (x)	Yield (%)
12/11	0.0	(10.8)	(36.2)	0.0	N/A	N/A
12/12	0.0	(11.7)	(36.3)	0.0	N/A	N/A
12/13e	0.0	(22.2)	(1.91)	0.0	N/A	N/A
12/14e	0.0	(39.9)	(2.39)	0.0	N/A	N/A

Source: Bloomberg

Price **\$17.44**
Market cap **\$268m**

Share price graph



Share details

Code **ESPR**
 Listing **NASDAQ**
 Sector **Pharma & biotech**
 Shares in issue **15.36m**

Business description

Esperion is developing therapeutics for elevated low-density lipoprotein cholesterol (LDL-C) and other cardiometabolic risk factors. Lead candidate ETC-1002 is in Phase II development in statin-intolerant and residual-risk hypercholesterolemia patients.

Bull

- Competitive LDL-C and hsCRP reductions with ETC-1002 and favourable safety profile.
- ETC-1002 novel mode of action adds potential for use with statins in residual risk patients.
- Preclinical assets: 4WF (HDL mimetic atherosclerosis) + ESP41091 (obesity/diabetes).

Bear

- Long development timeline in CVD indications; future financings and/or partnerships required.
- Increasing competition in hypercholesterolemia space (eg PCSK9 inhibitors).
- Partial clinical hold on ETC-1002 prevents studies >six months, until two-year pre-clinical carcinogenicity studies completed (due by YE14).

Analysts

Pooya Hemami +1 514 475 2384
 Christian Glennie +44 (0)20 3077 5727
 Robin Davison +44 (0)20 3077 5737

healthcare@edisongroup.com

EDISON QUICKVIEWS ARE NORMALLY ONE OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Berlin, Sydney and Wellington. Edison is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is not regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com.

DISCLAIMER

Copyright 2013 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is not registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE [2013]. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.

Berlin +49 (0)30 2088 9525
Friedrichstrasse 95
10117 Berlin
Germany

London +44 (0)20 3077 5700
280 High Holborn
London, WC1V 7EE
United Kingdom

New York +1 646 653 7026
245 Park Avenue, 39th Floor
10167, New York
US

Sydney +61 (0)2 9258 1162
Level 33, Australia Square
264 George St, Sydney
NSW 2000, Australia

Wellington +64 (0)4 8948 555
Level 15, 171 Featherston St
Wellington 6011
New Zealand